Month: January 2018

Sanofi to Acquire Bioverativ to Treat Hemophilia

Shots: Sanofi acquires Bioverativ, in all stock transaction with its Eloctate & Alprolix products. Bioverativ to receive $105/share in cash for a premium of 64 % with total deal value as $11.6B The focus of the agreement is to combine Bioverativ’s expertise with its platform for the advancement of fitusiran to treat Hemophilia A and […]Read More

Novartis’ Kisqali + Aromatase Inhibitor Receive FDA’s Breakthrough Therapy Designation

Shots: The FDA’s BT designation is based on P-III MONALEESA-7 study assessing Kisqali + tamoxifen/ aromatase inhibitor + goserelin vs tamoxifen/aromatase inhibitor + goserelin in 672 pre/perimenopausal women with HR+/HER2- advanced breast cancer The P-III MONALEESA-7 study results: mPFS (22.1, 27.5 vs 11.0, 13.8 mos.); AEs: neutropenia (60.6% vs. 3.6%); leukopenia (14.3% vs. 1.2%); no […]Read More